DBV Technologies SA
PAR:DBV

Watchlist Manager
DBV Technologies SA Logo
DBV Technologies SA
PAR:DBV
Watchlist
Price: 2.275 EUR 0.22% Market Closed
Market Cap: 409.1m EUR

DBV Technologies SA
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

DBV Technologies SA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
DBV Technologies SA
PAR:DBV
Net Income (Common)
-$122.6m
CAGR 3-Years
-17%
CAGR 5-Years
14%
CAGR 10-Years
-16%
Valneva SE
PAR:VLA
Net Income (Common)
-€85.5m
CAGR 3-Years
19%
CAGR 5-Years
-28%
CAGR 10-Years
-21%
Nanobiotix SA
PAR:NANO
Net Income (Common)
-€51.6m
CAGR 3-Years
-6%
CAGR 5-Years
-2%
CAGR 10-Years
-15%
Inventiva SA
PAR:IVA
Net Income (Common)
-€311.1m
CAGR 3-Years
-77%
CAGR 5-Years
-65%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Net Income (Common)
-$76.5m
CAGR 3-Years
24%
CAGR 5-Years
0%
CAGR 10-Years
-10%
Eurobio Scientific SA
PAR:ALERS
Net Income (Common)
€2.4m
CAGR 3-Years
-63%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
No Stocks Found

DBV Technologies SA
Glance View

Market Cap
409.1m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
HIDDEN
Show

See Also

What is DBV Technologies SA's Net Income (Common)?
Net Income (Common)
-122.6m USD

Based on the financial report for Jun 30, 2025, DBV Technologies SA's Net Income (Common) amounts to -122.6m USD.

What is DBV Technologies SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-16%

Over the last year, the Net Income (Common) growth was -39%. The average annual Net Income (Common) growth rates for DBV Technologies SA have been -17% over the past three years , 14% over the past five years , and -16% over the past ten years .

Back to Top